The Food and Drug Administration (“FDA”) has removed semaglutide from its drug shortage list after the agency determined the current supply of ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended. At Melrose ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The science-backed rise of GLP-1 medications and the role of compounded semaglutide in modern weight management. How Success by Sesame uses a telehealth weight loss program to provide affordable ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.